Advisory
Bryan Tegomoh, MD, MPH advises the institutions making consequential decisions about biological risk in the AI era: governments and biosecurity programs, funders, and the frontier labs whose models touch the life sciences. Engagements are independent and evidence-centered, held to the same standard as this handbook: where the real risk lies, where it does not, and what defense actually requires.
The chapters linked below are the public evidence base for the areas where independent review is most valuable.
Advisory Scope
For biosecurity, AI safety, and policy audiences, advisory work is most appropriate when a decision requires biological risk judgment, model-policy awareness, and practical understanding of safeguards:
- AI-biosecurity risk assessment for threat modeling, biological risk interpretation, and capability-risk review
- Red-teaming AI systems for evaluation design, misuse-risk testing, and safety controls
- DNA synthesis screening for sequence-screening policy, customer verification, and materials chokepoint strategy
- Digital biosurveillance for genomic surveillance, early-warning architecture, and response integration
- AI-bio governance and dual-use research oversight for model access, policy design, and layered defense
Advisory work is independent. It does not imply endorsement of a product, organization, or public claim.
Tell me the organization, the decision in front of you, and any materials worth reading first.